company background image
ILMN logo

Illumina NasdaqGS:ILMN Stock Report

Last Price

US$131.68

Market Cap

US$21.4b

7D

-9.9%

1Y

34.7%

Updated

20 Nov, 2024

Data

Company Financials +

Illumina, Inc.

NasdaqGS:ILMN Stock Report

Market Cap: US$21.4b

ILMN Stock Overview

Offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More details

ILMN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends1/6

Rewards

Trading at 12.5% below our estimate of its fair value

Earnings are forecast to grow 70.35% per year

Risk Analysis

No risks detected for ILMN from our risk checks.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Innovative Sequencing Advances Propel Growth Amidst Macroeconomic Challenges

Key Takeaways Enhanced customer collaboration and continuous innovation drive product adoption, boosting revenue and aligning developments with customer needs for advanced sequencing. Operational excellence, capital allocation, and NovaSeq X transition aim to improve profitability, offset pricing pressure, and drive shareholder value.
View narrative
US$164.60
FV
20.0% undervalued intrinsic discount
4.44%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Updated narrative

Illumina, Inc. Competitors

Waters

NYSE:WAT

US$20.5b

West Pharmaceutical Services

NYSE:WST

US$22.0b

Mettler-Toledo International

NYSE:MTD

US$24.5b

Avantor

NYSE:AVTR

US$13.4b

Price History & Performance

Summary of all time highs, changes and price drops for Illumina
Historical stock prices
Current Share PriceUS$131.68
52 Week HighUS$156.66
52 Week LowUS$93.51
Beta1.13
11 Month Change-9.32%
3 Month Change1.82%
1 Year Change34.70%
33 Year Change-63.98%
5 Year Change-58.97%
Change since IPO572.32%

Recent News & Updates

Illumina: Q3 Confirms Improving Fundamentals

Nov 05

We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Oct 21
We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Recent updates

Illumina: Q3 Confirms Improving Fundamentals

Nov 05

We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Oct 21
We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01
Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

May 26
Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina: Expect A Slow Rebound

May 07

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Apr 26
Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Mar 20
Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Feb 23

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Jan 26
Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Jan 19

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21
Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03
Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24
Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03
Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22
At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

The Big Trends: New Frontiers in Healthcare

Jul 13
The Big Trends: New Frontiers in Healthcare

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13
Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12
Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14
Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Shareholder Returns

ILMNUS Life SciencesUS Market
7D-9.9%-5.8%-1.0%
1Y34.7%1.7%30.3%

Return vs Industry: ILMN exceeded the US Life Sciences industry which returned 1.7% over the past year.

Return vs Market: ILMN exceeded the US Market which returned 30.3% over the past year.

Price Volatility

Is ILMN's price volatile compared to industry and market?
ILMN volatility
ILMN Average Weekly Movement5.0%
Life Sciences Industry Average Movement8.8%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: ILMN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ILMN's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199810,615Jacob Thaysenwww.illumina.com

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
ILMN fundamental statistics
Market capUS$21.41b
Earnings (TTM)-US$1.58b
Revenue (TTM)US$4.39b

4.8x

P/S Ratio

-13.2x

P/E Ratio

Is ILMN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ILMN income statement (TTM)
RevenueUS$4.39b
Cost of RevenueUS$1.42b
Gross ProfitUS$2.97b
Other ExpensesUS$4.55b
Earnings-US$1.58b

Last Reported Earnings

Sep 29, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-9.99
Gross Margin67.61%
Net Profit Margin-36.10%
Debt/Equity Ratio93.6%

How did ILMN perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

n/a

Payout Ratio